ASCO 2015 Highlights

Lorlatinib (Lorbrena) significantly improved progression-free survival (PFS) and intracranial response rates compared with the former standard of care, crizotinib (Xalkori), as first-line treatment for patients with advanced ALK-positive non–small-cell lung cancer (NSCLC), as reported in a planned interim analysis of the CROWN trial.

Utilization management tools and prior authorization are associated with delays in care for patients and high costs for physicians. In this session, panelists discuss the impact on cancer care, with an eye toward providing appropriate care while minimizing administrative burden.

With more than 1.8 million diagnoses of cancer per year in the United States, identifying malignancies at the earliest stage is priority among physicians. In this session, experts discuss the future of early-stage cancer diagnosis and how to improve cancer screenings.

Oncology nurse and patient navigators are playing an ever-increasing role in supporting patients with cancer and their caregivers. In this session, experts discuss the standardized measures and processes used by oncology nurse and patient navigators.

In this session, experts discuss the challenges faced at the beginning of the COVID-19 pandemic, how they worked to overcome them, and what lessons they will take with them into the future.

Specialized oncology pharmacy programs are playing an ever-increasing role in the complex delivery of care. In this session, panelists discuss the obstacles and successes of specialized oncology pharmacy programs.

In this session, a panel of experts share the Wall Street perspective on the opportunities and challenges ahead for cancer drug developers and healthcare providers.

Healthcare continues to adapt to the economic impact of the COVID-19 pandemic. In this session, industry experts discuss the underlying trends and economic realities of cancer care in the United States and global markets.

The increased complexity of new oncology drugs and the accelerated rate of their approval has led to greater demands from stakeholders across the cancer care continuum. In this session, panelists discuss oncology drug supply chain channels and how they are incorporated in the move to value-based care.

Numerous new innovations in stem-cell transplantation are coming to the market. In this session, experts offer the clinician, manufacturer, and payer perspectives regarding these new therapies.